Novo Nordisk registers Phase 3 trial for denecimig in acquired haemophilia A, plus new Phase 1 study
Two new Novo Nordisk trials appeared this week, one testing denecimig in acquired haemophilia A patients and another testing a novel compound in healthy volunteers.
Novo Nordisk registered two new studies this week, both listed as not yet recruiting.
- Denecimig (Mim8), a subcutaneous drug for acquired haemophilia A, is entering a Phase 3 trial called "FRONTIERAHA." The study is designed as an interventional trial with a single group intervention model and treatment as primary purpose, with an estimated enrollment of 84 participants.1 Its primary outcome is the number of treated bleeds, measured from treatment initiation at week 0 until the end of the main part at week 12.1
- NNC0642-1895, a new intravenous compound with no approved use yet, is starting a first-in-human Phase 1 study in healthy adults. The drug is being tested in humans for the first time and is not currently available for doctors to prescribe.2 The study will last about 94 days and has an estimated enrollment of 148 participants.2 Its primary outcome is the number of treatment emergent adverse events, tracked from pre-dose on Day 1 to Day 66.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.